Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry M Lopez

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 21, 2002
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitorsLarry M Lopez
Journal of the American Pharmacists Association : Japha|September 1, 2005
Rosuvastatin: a high-potency HMG-CoA reductase inhibitorLarry M Lopez
The Annals of Pharmacotherapy|April 1, 2004
Home blood pressure monitoring: point-of-care testingLarry M Lopez, James R Taylor
The Annals of Pharmacotherapy|June 5, 2004
Cholesterol: point-of-care testingJames R Taylor, Larry M Lopez
The Annals of Pharmacotherapy|December 31, 2009
Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practiceJ Daniel Robinson, Richard Segal, Larry M Lopez, et al.
Journal of the American Pharmacists Association : Japha|August 18, 2006
Increased cardiovascular risk with second-generation antipsychotic agent switchesL Douglas Ried, Bernard T Renner, Joel R McConkey, et al.
The Annals of Pharmacotherapy|March 30, 2006
Depressive symptoms in coronary artery disease patients after hypertension treatmentL Douglas Ried, Michael J Tueth, Michael D Taylor, et al.
American Heart Journal|February 22, 2003
Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trialJuan M Aranda, Richard S Schofield, Daniel F Pauly, et al.
Pharmacotherapy|March 28, 2009
Key articles and guidelines for the prevention of venous thromboembolismPaul P Dobesh, Ann K Wittkowsky, Zachary Stacy, et al.
Clinical Pharmacology and Therapeutics|April 4, 2006
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirementsChristina L Aquilante, Taimour Y Langaee, Larry M Lopez, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 21, 2002
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitorsLarry M Lopez
Journal of the American Pharmacists Association : Japha|September 1, 2005
Rosuvastatin: a high-potency HMG-CoA reductase inhibitorLarry M Lopez
The Annals of Pharmacotherapy|April 1, 2004
Home blood pressure monitoring: point-of-care testingLarry M Lopez, James R Taylor
The Annals of Pharmacotherapy|June 5, 2004
Cholesterol: point-of-care testingJames R Taylor, Larry M Lopez
The Annals of Pharmacotherapy|December 31, 2009
Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practiceJ Daniel Robinson, Richard Segal, Larry M Lopez, et al.
Journal of the American Pharmacists Association : Japha|August 18, 2006
Increased cardiovascular risk with second-generation antipsychotic agent switchesL Douglas Ried, Bernard T Renner, Joel R McConkey, et al.
The Annals of Pharmacotherapy|March 30, 2006
Depressive symptoms in coronary artery disease patients after hypertension treatmentL Douglas Ried, Michael J Tueth, Michael D Taylor, et al.
American Heart Journal|February 22, 2003
Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trialJuan M Aranda, Richard S Schofield, Daniel F Pauly, et al.
Pharmacotherapy|March 28, 2009
Key articles and guidelines for the prevention of venous thromboembolismPaul P Dobesh, Ann K Wittkowsky, Zachary Stacy, et al.
Clinical Pharmacology and Therapeutics|April 4, 2006
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirementsChristina L Aquilante, Taimour Y Langaee, Larry M Lopez, et al.
Pageof 1